Table 1.
Patients characteristics at time of serum sampling
Astrocytic tumors | Oligodendroglial tumors | |
---|---|---|
Number of patients | 41 | 29 |
Tumor grade | ||
WHO II | — | 14 (48%) |
WHO III | 12 (29%) | 15 (52%) |
WHO IV | 29 (71%) | — |
Gender | ||
Male | 26 (63%) | 14 (48%) |
Female | 15 (37%) | 15 (52%) |
Age (y) | ||
Median (range) | 58 (19–76) | 42.7 (28–68) |
Surgical procedure | ||
Craniotomy | 28 (68%) | 15 (52%) |
Stereotactic biopsy | 8 (20%) | 5 (17%) |
Not specified | 5 (12%) | 9 (31%) |
KPS | ||
Median (range) | 75% (40%–90%) (n = 34) | 90% (60%–100%) (n = 26) |
Preoperative MRI | ||
Contrast enhancement | 30 (73%) | 12 (45%) |
No enhancement | 6 (15%) | 8 (28%) |
Not specified | 5 (12%) | 8 (28%) |
Interval between surgery and serum sampling (mos) | ||
Median (range) | 1 (0.5–158) | 1 (0.5–168) |
Treatment at time of serum sampling | ||
Postsurgery pre-RT | 24 (59%) | 4 (14%) |
Ongoing RT | 3 (7%) | 1 (3%) |
Ongoing chemotherapy | 5 (12%) | 1 (3%) |
Surveillance | — | 13 (45%) |
Not reported | 9 (22%) | 10 (34%) |
KPS, Karnofsky performance status; RT, radiotherapy.